Drug intelligence / Profile preview

DOXA

Development stage: Preclinical
Lead developer: NLS Pharmaceutics
Modality: Small Molecules

Overview

DOXA (Dual Orexin Receptor Agonist) is a platform of novel small molecule dual orexin receptor agonists (OX1R and OX2R) being developed by NLS Pharmaceutics, licensed from Aexon Labs. These compounds are primarily targeted for the treatment of narcolepsy, with secondary applications in neurodegenerative conditions such as Parkinson's disease. The next-generation DOXA compounds feature a multi-target mechanism that includes the inhibition of Cathepsin H (CTSH), which is intended to prevent the destruction of orexin-producing cells and potentially slow disease progression.

Other names: Dual Orexin Receptor Agonist

Targets

CTSH (Cathepsin H)MRP (Multidrug resistance-associated protein family)HCRTR2 (Orexin/hypocretin receptor type 2)HCRTR1 (Orexin/hypocretin receptor type 1)

Beyond the preview

Go deeper on DOXA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DOXA.

Explore the full profile